JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has reiterated its Market Outperform rating on Cytokinetics (NASDAQ:CYTK) and maintained a price target of $78.
May 31, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating on Cytokinetics and maintained a price target of $78, indicating continued confidence in the company's performance.
The reiteration of a Market Outperform rating and a maintained price target of $78 by JMP Securities suggests strong confidence in Cytokinetics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100